Aliases & Classifications for Histiocytoma

MalaCards integrated aliases for Histiocytoma:

Name: Histiocytoma 12 29 44 15 73
Cutaneous Fibrous Histiocytoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4231
MeSH 44 D051642
NCIt 50 C35765
UMLS 73 C1509147

Summaries for Histiocytoma

MalaCards based summary : Histiocytoma, also known as cutaneous fibrous histiocytoma, is related to malignant fibrous histiocytoma of bone and fibrous histiocytoma. An important gene associated with Histiocytoma is MFHAS1 (Malignant Fibrous Histiocytoma Amplified Sequence 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 A histiocytoma is a tumour consisting of histiocytes. Histiocytes are cells that are a part of the... more...

Related Diseases for Histiocytoma

Diseases related to Histiocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 283)
# Related Disease Score Top Affiliating Genes
1 malignant fibrous histiocytoma of bone 33.4 CDK4 MDM2 MYOD1
2 fibrous histiocytoma 32.3 ATF1 CD163 CREB1 EWSR1 FUS MFHAS1
3 reticulohistiocytic granuloma 31.5 CD163 PTPRC SERPINA3
4 malignant fibroxanthoma 31.1 ALK CDK4 MDM2 MYOD1 PTPRC SERPINA3
5 soft tissue sarcoma 30.4 EWSR1 MDM2 TP53
6 dedifferentiated liposarcoma 30.3 CDK4 MDM2 TP53
7 histiocytosis 30.2 CD163 PTPRC SERPINA3
8 sarcoma 29.9 EWSR1 FUS KIT TP53
9 dermatofibrosarcoma protuberans 29.7 KIT SERPINA3 TP53
10 pleomorphic rhabdomyosarcoma 29.6 MB MYOD1
11 ewing's family of tumors 29.4 CDK4 EWSR1 KIT
12 myxoid chondrosarcoma 29.3 EWSR1 MTAP
13 fibrosarcoma of bone 29.1 CDK4 KIT MDM2 SERPINA3
14 undifferentiated embryonal sarcoma of the liver 29.1 CDK4 MDM2 MYOD1 SERPINA3
15 leiomyosarcoma 28.6 CDK4 KIT MB MDM2 TP53
16 myxoid liposarcoma 28.5 ATF1 CDK4 EWSR1 FUS MDM2 TP53
17 lymphoma, non-hodgkin, familial 28.5 ALK MDM2 PTPRC TP53
18 adenocarcinoma 28.3 ALK CDK4 KIT TP53
19 inflammatory myofibroblastic tumor 28.3 ALK KIT MDM2 TP53
20 liposarcoma 27.6 CDK4 EWSR1 FUS MB MDM2 TP53
21 embryonal sarcoma 27.6 CDK4 KIT MDM2 MYOD1 SERPINA3 TP53
22 rhabdomyosarcoma 26.1 ALK CDK4 EWSR1 MB MDM2 MYOD1
23 diaphyseal medullary stenosis with malignant fibrous histiocytoma 12.5
24 histiocytoma, angiomatoid fibrous 12.4
25 cutaneous fibrous histiocytoma 12.3
26 malignant skin fibrous histiocytoma 11.9
27 benign deep fibrous histiocytoma 11.9
28 generalized eruptive histiocytosis 11.8
29 undifferentiated pleomorphic sarcoma 11.8
30 sclerosing hemangioma 11.7
31 myxofibrosarcoma 11.7
32 tenosynovial giant cell tumor 11.0
33 sarcomatosis 10.9 ATF1 EWSR1
34 urachal cancer 10.9
35 pigmented villonodular synovitis 10.8
36 conventional central osteosarcoma 10.7 EWSR1 MDM2
37 melanoma of soft tissue 10.7 ATF1 CREB1 EWSR1
38 proliferative fasciitis 10.7 MB SERPINA3
39 extraosseous chondrosarcoma 10.7 EWSR1 FUS
40 infiltrating angiolipoma 10.7 CDK4 MDM2
41 spindle cell lipoma 10.6 CDK4 MDM2
42 zika virus infection 10.6 MDM2 TP53
43 nodular tenosynovitis 10.6 PTPRC SERPINA3
44 actinic cheilitis 10.6 MDM2 TP53
45 lipoblastoma 10.6 CDK4 MDM2
46 meninges sarcoma 10.5 MB TP53
47 juxtacortical chondroma 10.5 EWSR1 FUS
48 bone osteosarcoma 10.5 CDK4 EWSR1 MDM2
49 dermis tumor 10.5 CD163 SERPINA3
50 lip cancer 10.5 MDM2 TP53

Graphical network of the top 20 diseases related to Histiocytoma:



Diseases related to Histiocytoma

Symptoms & Phenotypes for Histiocytoma

GenomeRNAi Phenotypes related to Histiocytoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 9.6 CD163
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.6 CD163
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.6 CD163
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.6 FUS
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.6 CD163
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.6 CD163
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.6 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.6 EWSR1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.6 FUS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.6 CDK4 EWSR1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.6 FUS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.6 CD163 CDK4 EWSR1 FUS
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.6 EWSR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.6 EWSR1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.6 CD163

MGI Mouse Phenotypes related to Histiocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 KIT MB MDM2 MTAP MYOD1 CD163
2 muscle MP:0005369 9.86 KIT MB MDM2 MYOD1 CD163 TP53
3 neoplasm MP:0002006 9.7 KIT MDM2 MYOD1 ALK PTPRC TP53
4 pigmentation MP:0001186 9.35 KIT MDM2 ALK TP53 CDK4
5 respiratory system MP:0005388 9.28 KIT MB MTAP MYOD1 ALK PTPRC

Drugs & Therapeutics for Histiocytoma

Drugs for Histiocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
4
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
13
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
14 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
20 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
21 Etoposide phosphate Phase 3,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
26
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Indinavir Approved Phase 2 150378-17-9 5362440
30
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
33
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
34
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177
35
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
36
Bevacizumab Approved, Investigational Phase 2 216974-75-3
37
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 5284616 6436030 46835353
38
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
39
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
40
nivolumab Approved Phase 2,Phase 1 946414-94-4
41
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
42
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
43
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
45
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
48 Exatecan Investigational Phase 2 171335-80-1
49
Camptothecin Experimental Phase 2 7689-03-4
50
Saracatinib Investigational Phase 2 379231-04-6

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
27 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
28 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
30 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
31 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
33 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
34 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
35 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
36 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
37 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
38 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
39 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
40 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
41 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
42 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
43 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
44 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
45 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
46 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Active, not recruiting NCT01962103 Phase 1, Phase 2 nab-paclitaxel
47 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
48 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
49 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
50 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib

Search NIH Clinical Center for Histiocytoma

Cochrane evidence based reviews: histiocytoma

Genetic Tests for Histiocytoma

Genetic tests related to Histiocytoma:

# Genetic test Affiliating Genes
1 Histiocytoma 29

Anatomical Context for Histiocytoma

MalaCards organs/tissues related to Histiocytoma:

41
Bone, Lung, Skin, Liver, Heart, Pancreas, Colon

Publications for Histiocytoma

Articles related to Histiocytoma:

(show top 50) (show all 958)
# Title Authors Year
1
Giant malignant fibrous histiocytoma of the testis. ( 29484233 )
2018
2
Retroperitoneal Angiomatoid Fibrous Histiocytoma Presenting as a Recurrent Spontaneous Retroperitoneal Hemorrhage in a 9-Year-Old Boy. ( 29432314 )
2018
3
Primary intracranial angiomatoid fibrous histiocytoma: a case report and literature review. ( 29540076 )
2018
4
Epithelioid cell histiocytoma with SQSTM1-ALK fusion: a case report. ( 29747676 )
2018
5
ALK Expression in Angiomatoid Fibrous Histiocytoma: A Potential Diagnostic Pitfall. ( 29877921 )
2018
6
Therapeutic response of metastatic angiomatoid fibrous histiocytoma carrying EWSR1-CREB1 fusion to the interleukin-6 receptor antibody tocilizumab. ( 29932283 )
2018
7
Giant Aneurysmal Benign Fibrous Histiocytoma (Dermatofibroma). ( 29956351 )
2018
8
Low-Grade Malignant Fibrous Histiocytoma Originating From the Medial Rectus Muscle. ( 29538190 )
2018
9
Immunohistochemical Labeling of Multiple Myeloma Oncogene 1/Interferon Regulatory Factor 4 (MUM1/IRF-4) in Canine Cutaneous Histiocytoma. ( 29444632 )
2018
10
Angiomatoid Fibrous Histiocytoma With Paraneoplastic Platelet Storage Pool Deficiency. ( 29472492 )
2018
11
A subset of so-called dermal non-neural granular cell tumours are underlined by ALK fusions, further supporting the idea that they represent a variant of epithelioid fibrous histiocytoma. ( 29742298 )
2018
12
Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases. ( 29327718 )
2018
13
ALK Gene Fusions in Epithelioid Fibrous Histiocytoma: A Study of 14 Cases, With New Histopathological Findings. ( 29329131 )
2018
14
&amp;quot;Chondroblastoma-like&amp;quot; epithelioid fibrous histiocytoma: A previously undescribed and potentially confusing variant. ( 29068085 )
2018
15
Fibrous Histiocytoma of the Lacrimal Sac in an 11-Year-Old Male. ( 29494378 )
2018
16
Unusual Uptake of 131I in a Cutaneous Benign Fibrous Histiocytoma in a Patient With Thyroid Cancer. ( 29076899 )
2018
17
ESWR1-CREM Fusion in an Intracranial Myxoid Angiomatoid Fibrous Histiocytoma-Like Tumor: A Case Report and Literature Review. ( 29788195 )
2018
18
Primary Hepatic Malignant Fibrous Histiocytoma on PET/CT. ( 29485437 )
2018
19
Spindle cell predominant epithelioid fibrous histiocytoma. ( 29430713 )
2018
20
A Case of Angiomatoid Fibrous Histiocytoma Presenting as Subcutaneous Nodule in a 4-Year-Old Girl. ( 29606824 )
2018
21
Intracranial malignant fibrous histiocytoma. ( 29685317 )
2018
22
Treatment outcomes of malignant fibrous histiocytoma of the maxillary sinus. ( 28901310 )
2017
23
Malignant fibrous histiocytoma masquerading as pyogenic granuloma. ( 28388346 )
2017
24
Primary Pulmonary Malignant Fibrous Histiocytoma. ( 29404161 )
2017
25
Primary pulmonary malignant fibrous histiocytoma: case report and literature review. ( 28932590 )
2017
26
Benign Fibrous Histiocytoma: An Uncommon Presentation. ( 28892910 )
2017
27
18F-FDG Uptake in Benign Fibrous Histiocytoma of Adrenal Gland: A Potential Pitfall. ( 28632691 )
2017
28
Deep Benign Fibrous Histiocytoma of the Anterior Mediastinum Mimicking Malignancy. ( 28497381 )
2017
29
TLE-1-Positive Angiomatoid Fibrous Histiocytoma Mimicking Synovial Sarcoma. ( 28248724 )
2017
30
Malignant fibrous histiocytoma: Database review suggests a favorable prognosis in the head and neck. ( 28988458 )
2017
31
Malignant fibrous histiocytoma in the right portion of the mandible with metastasis in pancreas. ( 29040904 )
2017
32
Angiomatoid fibrous histiocytoma of the scalp mimicking cutaneous angiosarcoma in incisional biopsy containing CD31-positive histiocytes: A potential histopathological pitfall. ( 28370384 )
2017
33
Aneurysmal Variant of Fibrous Histiocytoma- A Rare Entity Known for Recurrence. ( 28764178 )
2017
34
Malignant fibrous histiocytoma arising from renal capsule: An extremely rare entity. ( 28937382 )
2017
35
En bloc resection and prosthesis implantation to treat malignant fibrous histiocytoma of the humerus. ( 29068573 )
2017
36
Cholesterotic Fibrous Histiocytoma in a Patient with Metabolic Syndrome. ( 29033817 )
2017
37
Primary hepatic malignant fibrous histiocytoma combined with invasion of inferior vena cava: A case report and literature review. ( 28591058 )
2017
38
Retrovesical malignant fibrous histiocytoma: a rare tumor. ( 29197849 )
2017
39
Two cases of benign fibrous histiocytomas (dermatofibromas) associated with Langerhans cell histiocytosis. ( 28941307 )
2017
40
CORR Insights(Ar): Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma. ( 28656494 )
2017
41
Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma. ( 28536856 )
2017
42
Aneurysmal fibrous histiocytoma - spindle cell tumour with pigment: A diagnostic dilemma on cytology. ( 28727241 )
2017
43
Dermoscopy and reflectance confocal microscopy of osteoclastic deep benign fibrous histiocytoma. ( 28895663 )
2017
44
Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity? ( 28281318 )
2017
45
Dermoscopic findings in an early malignant fibrous histiocytoma on the face. ( 29085719 )
2017
46
Cholesterotic fibrous histiocytoma with no associated dyslipidemia. ( 28303567 )
2017
47
A Rare Case of Malignant Fibrous Histiocytoma (Undifferentiated High-Grade Pleomorphic Sarcoma) of Malar Region. ( 28468216 )
2017
48
Malignant fibrous histiocytoma in a patient presenting with urinary system symptoms. ( 29451657 )
2017
49
Benign Fibrous Histiocytoma: A Rare Case Report and Literature Review. ( 26929563 )
2016
50
Double primary malignant fibrous histiocytoma and squamous cell carcinoma of the larynx treated with laser laryngeal conservation surgery. ( 27170836 )
2016

Variations for Histiocytoma

Expression for Histiocytoma

Search GEO for disease gene expression data for Histiocytoma.

Pathways for Histiocytoma

Pathways related to Histiocytoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 CDK4 CREB1 KIT MDM2 TP53
2
Show member pathways
12.71 CDK4 CREB1 KIT MDM2 TP53
3 12.66 ALK CDK4 KIT MDM2 TP53
4
Show member pathways
12.42 CDK4 CREB1 MDM2 TP53
5 12.26 ATF1 CDK4 CREB1 TP53
6
Show member pathways
12.16 CDK4 CREB1 MDM2 TP53
7 12.04 CDK4 CREB1 MDM2 TP53
8 11.91 CDK4 CREB1 MDM2 TP53
9
Show member pathways
11.9 CREB1 MDM2 TP53
10 11.85 CD163 KIT PTPRC
11 11.82 CDK4 MDM2 TP53
12 11.82 ATF1 EWSR1 FUS MDM2 TP53
13 11.75 ATF1 CREB1 MYOD1
14 11.7 CDK4 MDM2 TP53
15
Show member pathways
11.69 CREB1 MDM2 TP53
16 11.65 CREB1 MDM2 TP53
17 11.59 CDK4 CREB1 MYOD1
18 11.56 CD163 KIT PTPRC
19 11.54 ATF1 CDK4 CREB1 MDM2 TP53
20 11.52 CDK4 MDM2 TP53
21 11.31 CREB1 MDM2 TP53
22 11.19 CDK4 MDM2 TP53
23 11.04 ATF1 CREB1 TP53
24 10.94 CDK4 MDM2 TP53
25 10.9 ATF1 CREB1
26 10.59 ATF1 CDK4 MDM2 TP53

GO Terms for Histiocytoma

Cellular components related to Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.92 ATF1 CDK4 CREB1 MYOD1

Biological processes related to Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.55 ALK CDK4 CREB1 KIT MYOD1
2 positive regulation of protein export from nucleus GO:0046827 9.26 MDM2 TP53
3 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 8.96 CREB1 TP53
4 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription coregulator activity GO:0003712 9.43 CREB1 EWSR1 FUS
2 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.33 ATF1 CREB1 MYOD1
3 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding GO:0001228 9.26 ATF1 CREB1 MYOD1 TP53
4 identical protein binding GO:0042802 9.23 ALK ATF1 CREB1 EWSR1 FUS MDM2
5 protein binding GO:0005515 10.2 ALK ATF1 CD163 CDK4 CREB1 EWSR1

Sources for Histiocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....